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Abstract
Objectives Pathogenesis of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is not fully explained. An antiangiogenic
effect of bisphosphonates (BPs) or an altered bone quality have been advocated. The aims of the present study were to analyze
alveolar mandibular vascularization and bone quality in rats with BRONJ.
Materials and methods Thirty-eight Sprague-Dawley rats were randomized into two groups: zoledronic acid (ZA), n = 27, and
control (CTRL) n = 11. The ZA group received a weekly IV injection of ZA (100 μg/kg) during 10 weeks. The CTRL group
received saline. After 6 weeks, extraction of the right mandibular molars was performed. Rats were sacrificed after 14 weeks.
Microtomography characterized bone lesions and vascularization after injection of a radio-opaque material. Raman
microspectroscopy evaluated bone mineralization.
Results Fifty-five percent of ZA rats presented bone exposure and signs of BRONJ. None sign was found at the left
hemimandible in the ZA group and in the CTRL group. Vascular density appeared significantly increased in the right
hemimandibles of the CTRL group compared to the left hemimandibles. Vascularization was reduced in the ZA group. A
significantly increased of the mineral-to-amide ratio was found in the alveolar bone of ZA rats by Raman microspectroscopy.
Conclusions In a rat model of BRONJ, microtomography evidenced osteonecrosis in BRONJ. Raman spectroscopy showed an
increased mineralization. Vascularization after tooth extraction was impaired by ZA.
Clinical relevance Prolonged BP administration caused an increase in the mineralization and a quantitative reduction of the
vascularization in the alveolar bone; both factors might be involved concomitantly in the BRONJ pathophysiology.
Keywords Bisphosphonate . BRONJ . Rat model . Osteonecrosis . Vascularization . Raman microspectroscopy .
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Introduction
Bisphosphonates (BPs) are structural analogs of inorganic pyro-
phosphate, and they are resistant to enzymatic hydrolysis. They
have a strong affinity for the hydroxyapatite crystal and can
remain several years in bone. They inhibit bone resorption by
interfering with the mevalonate pathway in the osteoclast [1]. A
large number of studies have confirmed their interest in reducing
the incidence of osteoporosis-related fractures by increasing
bone mineral density (BMD) [2, 3]. In human, intravenous
amino-BPs injections are used in several indications such as
osteoporosis, bone metastases, multiple myeloma, or hypercal-
cemia associated with an increased osteoclast number [4, 5].
Antiresorptive drug-related osteonecrosis of the jaw
(ARONJ) is a major adverse event due to antiresorptive treat-
ments and was first described with BP [6–9]. It is clinically
defined as an area of exposed bone of the jaws that do not heal
within 8 weeks after identification in a patient with an
antiresorptive drug history and without irradiation therapy to
the craniofacial region [10, 11]. The incidence of
* Daniel Chappard
daniel.chappard@univ–angers.fr
1 Groupe d’Etude RemodelageOsseux et bioMatériauxGEROM, SFR
42-08, IRIS-IBS Institut de Biologie en Santé, Université d’Angers,
CHU d’Angers 4, rue Larrey, 49933 Angers Cedex, France
2 Service de chirurgie maxillo-faciale et stomatologie, CHU d’Angers,
4, rue Larrey, 49933 Angers Cedex, France
3 SCIAM Service Commun d’Imagerie et Analyses Microscopiques,
IRIS-IBS Institut de Biologie en Santé, Université d’Angers, CHU
d’Angers 4, rue Larrey, 49933 Angers Cedex, France
Clinical Oral Investigations
https://doi.org/10.1007/s00784-018-2385-2
bisphosphonate-related osteonecrosis of the jaw (BRONJ)
ranges between 1% and 10% in patients undergoing IV
BP therapy [12, 13]. The highest risk is in patients with
multiple myeloma receiving iv zoledronic acid (ZA) treat-
ment [14]. BRONJ is more often located at the mandible
(70%) than at the maxilla (30%) [15]. A triggering factor
with bone exposure (mainly consisting in tooth extractions)
is found in the majority of cases [10, 15–18]. A BP ther-
apy is often considered as a contraindication to dental
implant treatment [19–21].
The pathogenesis of BRONJ seems multifactorial but
is not fully explained yet [22–24]. An explanation could
be an impairment of jaw bone vascularization due to an
antiangiogenic effect of BPs [25–29]. The role of bone
quality with an increased stiffness of the bone matrix,
due to a uniformity of the mineralization degree, has
also been advocated [30]. Another explanation could
be a direct toxicity of BPs for epithelial cells combined
with a reduced microcirculation of the gingiva [22, 31].
The development of chronic osteomyelitis due to a con-
tamination with Actynomyces is reported [22, 32].
An animal model mimicking the clinical features of
BRONJ may help to understand the pathophysiologi-
cal mechanisms of BRONJ and evaluate new treat-
ments. Several models have been described in labora-
tory animals, but none of them reproduce strictly the
clinical characteristics observed in the human disease
[33–36].
The aims of the present study were to provoke BRONJ in
the rat and to analyze the mandibular vascularization after
intravascular injection of a radio-opaque material. The quality
of the bone material was also assessed by Raman
microspectrometry and quantitative backscattered electron
imaging (qBEI) to evaluate the mineralization degree of the
bone matrix.
Material and methods
Animals and experimental procedure
Animal care and experimental protocols were approved by the
French Ministry of Research and were done in accordance
with the institutional guidelines of the French Ethical
Committee (protocol agreement number 01857.01), the
European Communities Council Directive of 24 November
1986 (86/609/EEC) and under the supervision of authorized
investigators. The flowchart of the study appears in (Fig. 1).
Fifteen-week-old male Sprague-Dawley rats (n = 38),
weighing 486.3 ± 10.8 g, were used for the study (Janvier-
Labs, Le Genest-Saint-Isle, France). They were acclimated
for 2 weeks to the local vivarium conditions (24 °C and
12 h/12 h light dark cycle) where they were given standard
laboratory food (UAR, Villemoison-sur-Orge, France) and
water ad libitum. Rats were randomized into two groups: a
control group (CTRL, n = 11) and a zoledronic acid group
(ZA, n = 27). Rats from the ZA group were anesthetized with
isoflurane and injected intravenously with ZA (Zometa®,
Novartis Pharma GmbH, Nuremberg, Germany) at a dose of
100 μg/kg, once a week, during 10 weeks. Injections were
performed in a tail vein. Each animal of the ZA group received
a total dose of ZA of 1000 μg/kg at the end of the protocol.
Rats of the CTRL group were similarly injected with equiva-
lent volume of saline solution. At sixth week, extractions of
the three right mandibular molars were performed in rats of
both group (see below). Rats were weighted weekly and
sacrificed 14 weeks after the first injection by CO2 inhalation.
Visual examination of mandibular molar regions was per-
formed in order to look for exposed bone. Rats were then
randomized in two subgroups: subgroup A and subgroup B.
CTRLA and ZAA groups were used for micro-CT, Raman
microspectrometry, and qBEI analysis; CTRLB and ZAB
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Fig. 1 Flowchart of the study
showing animal repartitions in
control group (CTRL) and
zoledronic acid group (ZA) and in
subgroup A (CTRLA and ZAA)
and subgroup B (CTRLB and
ZAB)
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groups were injected with barium sulfate for vascularization
analysis. Hemimandibles were then dissected, defleshed, and
fixed in formalin during 24 h and transferred in absolute acetone.
Tooth extractions
Extraction of the molars was done as follows. General anesthesia
was induced by intraperitoneal injection of 100 mg/kg ketamine
(Renaudin, Aïnhoa, France) and 10 mg/kg xylazine (Rompun®
2%, Bayer, Leverkusen, Germany). Analgesia was obtained
using subcutaneous injections of buprenorphine (Vetergesic®,
Sogeval, Laval, France) at a dose of 0.03 mg/kg, half an hour
before surgical procedure and postoperatively if needed. Tooth
extraction was performed using rodent specific instrumentation
(Coveto, Montaigu, France). Adequate exposure was obtained
using a mouth gag and rodent cheek dilator with lingual traction.
Each tooth was removed progressively using a Crossley molar
luxator and a molar extractor. The first molar was separated into
two halves with the luxator before removing. If needed, hemo-
stasis was obtained with simple compression and no suture was
done. No additional drug and no antibiotic was given. Rats were
closely monitored until awakening.
Microcomputed tomography
Micro-CT of the right and left hemimandibles was performed
using a Skyscan 1172 X-ray computerized microtomograph
(Bruker microCT, Kontich, Belgium) equipped with an X-ray
tube working at 70 kV/100 μA. Bones were placed in
Eppendorf’s tubes filled with water to prevent desiccation. The
tubes were fixed on a brass stub with plasticine. Analysis was
done with a pixel size corresponding to 10.5 μm; the rotation
step was fixed at 0.25° and exposure was done with a 0.5-mm
aluminum filter. For each hemimandible, a stack of 2D sections
was obtained and reconstructed using NRecon software
(Bruker) and analyzed with CTan software (Skyscan, re-
lease 1.13.11.0). Frontal, axial, and sagittal sections of al-
veolar regions were then obtained from 3D models using a
surface-rendering program (Ant, release 2.0.5, Skyscan,
Belgium). Three-dimensional reconstructions were obtain-
ed using CTVox software (Skyscan, release 2.5).
Raman microspectroscopic analysis
The left hemimandibles were used to evaluate bone quality at
the alveolar bone where no tooth extraction had been done.
Bone samples were immersed in sodium hypochlorite (50%
in water) to remove organic tissues, rinsed 4 times in ultrapure
water, and dried at room temperature. They were then polished
on a grinding machine (Struers, Copenhagen, Denmark) using
ascending grads of polishing paper (1200, 2000, and 4000)
during 2 min each to expose the alveolar bone and the teeth
roots. Bones were affixed onto glass slides with a hand press to
obtain a horizontal surface parallel to the slide. Raman analyses
were performed on a Senterra microscope with the OPUS 5.5
software (Bruker optic, Ettlingen, Germany). The excitation
laser wavelength was 785 nm with an excitation power of
50 mWand 8–12 cm−1 spectral resolution to avoid the autoflu-
orescence of the collagen. For each sample, the final spectrum
was obtained by averaging 20 scans of 40 s. Average Raman
spectra were obtained for control alveolar bone; ZA impregnat-
ed alveolar bone and dehydrated ZA from all rats from groupA.
An automatic baseline was applied, and four physicochemical
parameters were determined from spectra [37]:
& Mineralization (mineral to matrix ratio) is the intensity
ratio between the ν1PO4 (960 cm
−1) peak to the matrix
bands (amide I 1667 cm−1 or amide III 1243 cm−1).
& Carbonate substitution is the intensity ratio between
B-type CO3
2− (1071 cm−1) band and the ν1PO4
(960 cm−1) band.
& Relative proteoglycan (PG) content is the ratio of GAG/
CH3 (1365–1390 cm
−1) to the amide III band.
& Crystallinity is the inverse of the full width at half maxi-
mum intensity of the ν1PO4 band (960 cm
−1).
ZA spectrum was obtained from a sample of dehydrated
ZA using the same procedure.
Quantitative backscattered electron imaging
and energy-dispersive X-ray spectroscopy
Quantitative backscattered electron imaging was employed to
determine the bone mineral density distribution (BMDD) in the
same regions of alveolar bone as Raman analysis as previously
reported. This methodology has been described in full details
elsewhere [38, 39]. Bone samples were embedded undecalcified
in poly (methylmethacrylate), and the blocks were polished to a
0.5-μm finish with diamond particles, carbon-coated, and ob-
served with a scanning electron microscope (EVO LS10, Carl
Zeiss Ltd., Nanterre, France) equipped with a five quadrants
semi-conductor backscattered electron detector. Themicroscope
was operated at 20 keV with a probe current of 250 pA and a
working distance of 15 mm. The alveolar bone area located and
imaged at a × 100 nominal magnification, corresponding to a
pixel size of 1.1 μm per pixel. Four images per samples were
taken, and the gray-level distribution of each image was ana-
lyzed with a lab-made routine in ImageJ. Three variables were
obtained from the bone mineral density distribution: Capeak as
the most frequently observed calcium concentration, Camean as
the average calcium concentration, and Cawidth as the width of
the histogram at half maximum of the peak.
Furthermore, the elemental atomic bone composition was
determined by energy-dispersive X-ray spectroscopy (EDS)
with a 20 mm2 X-max detector (Oxford Instruments,
Abingdon, UK) fitted in the SEM and the Inca software. The
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Ca/P ratio was computerized as the atomic ratio between cal-
cium and phosphorus percent.
Analysis of bone vascularization
Catheterism of the right common carotid artery was done using a
24G catheter (Introcan Safety®, BBraun, Melsungen, Germany)
under a binocular microscope (Leica, Weitzlar, Germany) with
microsurgical specific instrumentation. Ligature of the catheter
was done with an 8/0 suture thread. Venotomy of the right inter-
nal jugular vein was done to ensure blood drainage. First, a
vascular rinse was performed using 5 ml of heparinized saline
(Héparine sodique, Panpharma, Fougères, France). A solution
composed of 5% of gelatin and 95% of a commercial barium
sulfate solution used for digestive X-ray analysis (Micropaque®,
Guerbet, Roissy, France) was prepared by heating at 37 °C.
Then, 4 ml of this warmed solution were injected through the
catheter. Ligature of the right and left common carotid arteries
and the right and left internal jugular veins were done so that the
solution remains in the injected vessels. The injected animals
were placed in a cold room (4 °C) for 24 h to allow hardening
of the vascular injection fluid. Hemimandibles were then dissect-
ed, defleshed, and fixed in formalin until use.
Micro-CT examination was done as described for micro-
vascular analysis [40]. Briefly, a first micro-CT acquisition
was done as described above. Samples were then decalcified
using a mixture composed of 4% of formic acid, 10% of for-
malin in distilled water, changed twice a day, during 6 days.
Decalcified samples were then rinsed in tap water to remove
acid remnants and kept in formalin until use. A second micro-
CT was then performed with the same procedure except for
the rotation step which was fixed at 0.10° to allow better detail
identification. So, for each hemimandible, two stacks of 2D
sections were obtained (undecalcified and decalcified sam-
ples) and reconstructed using NRecon software (Bruker). 3D
vascular reconstructions were obtained using VG Studio
MAX 2.1 software (Volume Graphics GmbH, Heidelberg,
Germany). 3D vascular volume of the alveolar bone (VV/
TVALV, in %) was measured using CTAn software (Bruker).
The reference volume of alveolar bone tissue TVALV was se-
lected by a routine facility of the software after overimposing
the 3D model obtained on the 1st scan prior to decalcification
to the 2nd scan of the decalcified mandible. Technical details
have been described previously [40].
Statistical analysis
Statistical analysis was performed using the Systat statistical
software release 13.0 (Systat Software Inc., San Jose, CA). All
data were expressed as mean ± standard error of the mean
(SEM). Differences between groups were analyzed by a
non-parametric test (Kruskall-Wallis). Differences were con-
sidered significant when p < 0.05.
Results
Animal loss and body weight
Eight rats died before sacrifice: three in the CTRL group and
five in the ZA group. One rat died after an intravenous injec-
tion of ZA, seven rats died during the surgical procedure. In
each group, the remaining rats were randomized in two sub-
groups: subgroup A and subgroup B (Fig. 1).
All rats gained weight during all time period of the study.
Weight gain was 9.8 ± 0.7 g per week (12.5 ± 1.6 g for the
CTRL group and 8.7 ± 0.7 g for the ZA group). Aweight loss
occurred during the 2 weeks following the tooth extraction
procedure. The average weight loss was − 12.6 ± 2.2 g (i.e.,
− 2.16% of pre-extraction weight) with − 19.7 ± 5.8 g for the
CTRL group and − 10.1 ± 1.8 g for the ZA group. No statis-
tical difference was found between groups for any of these
parameters at any time.
Macroscopic examination
Fifty-five percent of ZA-treated rats had an impaired
healing with BRONJ lesions, consisting in mucosal ulcer-
ations with large bone exposures, at the teeth extraction site
(Fig. 2). No exposed mandibular bone was found in other
locations. Normal wound healing with intact overlying mu-
cosa and no bone exposure was observed in all rats of the
CTRL group.
Fig. 2 Macroscopic aspects of extraction sites after sacrifice showing
bone exposure in a ZA-treated rat (a) and normal wound healing with
no bone exposure in a CTRL rat (b). The scale bars stand for 2 mm
Clin Oral Invest
Micro-CT analysis
Micro-CT analysis revealed typical signs of BRONJ: cortical
osteolysis (n = 9), periosteal reaction (n = 4), and bone seques-
tration (n = 2) at the right molar area in rats of the ZAA group
(n = 11). 2D sections were obtained by a virtual cutting plane
passing through the socket of the first molar or horizontally to
identify periosteal reaction and bone sequestration (Fig. 3). No
signs of BRONJ were found on the left hemimandibles of the
ZAA group nor on the right and left hemimandibles of the
CTRL group. Tooth root remnants were noticed in the extrac-
tion sockets.
Raman analysis
The averaged Raman spectra of control alveolar bone, ZA im-
pregnated alveolar bone and ZA are shown in Fig. 4. No differ-
ence between the spectra of control bone and ZA impregnated
bone could be evidenced. The imidazole ring characteristic of
ZA was undetectable in ZA impregnated bone. Mineralization
ratio was found significantly increased in the ZAA group
(Table 1). Other parameters derived from Raman spectra did
not significantly differ between ZAA and CTRLA animals.
SEM-qBEI and EDS analysis
No significant differences were found for any of the qBEI
parameters (Camean, Capeak, and Cawidth) between ZAA and
CTRLA animals (Table 2). The Ca/P ratio did not significantly
differ between the ZAA and CTRLA groups.
Vascularization analysis
3D reconstructions of microvessels of alveolar bone were ob-
tained (Fig. 5). The pedicle of the nervus alveolaris inferior
was well seen and could be easily followed, the technique was
also able to characterize the very thin capillaries in the alveolar
region. On the 3D reconstructions, the vascular density
seemed increased in the right hemimandible of CTRLB group
after the tooth extraction. The vascular density also appeared
reduced in the right hemimandibles of the ZAB group, but no
difference was noticed at naked eye on the 3D reconstructions
between the density of the vascular bed on the left side of the
CTRL and ZA animals. When VV/TVALV was measured, a
significant difference was evidenced between the left and right
side of the CTRL group (Fig. 6). A significant reduction of the
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Fig. 4 Raman spectra of control alveolar bone (a), ZA impregnated
alveolar bone (b), and dehydrated ZA (c). ZA spectrum is undetectable
in the ZA impregnated bone
Fig. 3 Micro-CT analysis of alveolar bone modifications. 2D frontal
sections of the right (a) and left (b) hemimandible of a rat of the ZA
group. c 2D axial section of a right hemimandible of a rat of the ZA
group showing periosteal reaction on the lingual side (black arrows)
and bone sequestration (arrowhead) on the vestibular side. Tooth root
remnants can be noticed in the extraction sockets
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vascular bed was also evidenced when comparing the right
side of the ZAR and the CTRLR group.
Discussion
Clinically exposed bone is the main element of the clinical
diagnosis of BRONJ in human. Our animal model’s charac-
teristics are close to those found in the literature [33, 35,
41–44]. The rat is the most used animal model for the devel-
opment of bisphosphonates osteonecrosis of the jaw [33]. ZA
doses used in the present study were very high (400 μg/kg per
month) and are equivalent to those used in clinical practice for
the treatment of myeloma in human [27, 45]. The use of high
doses and long-lasting treatment are known to significantly
increase the chance to develop BRONJ lesions [46]. We chose
to use IV injection because it has the highest success rates in
models of the literature and because it is similar to human
clinic [42, 45, 47]. Tooth extraction was selected here as a
triggering factor since BRONJ occurs after a tooth extraction
in 60% of patients [15]. Similarly, we performed mandibular
rather than maxillary tooth extraction, despite its difficulty,
because BRONJ occurs more frequently at the mandible in
70% of the patients [48, 49]. Selected animals were free of
Table 1 Comparison between averages of spectroscopic parameters for each group after Raman analysis
ZA CTRL p
Mineral/amide I 38.94 ± 1.40 32.94 ± 1.91 0.03
Mineral/amide III 72.10 ± 4.94 52.05 ± 4.70 0.02
Carbonate substitution 0.133 ± 0.002 0.131 ± 0.005 NS
Crystallinity 111×10
-6
111×10
-6
NS
PG content 0.198 ± 0.071 0.173 ± 0.043 NS
The gray boxes highlight a significant difference between ZA vs. CTRL
Fig. 5 a 3D micro-CTof the vascular bed in the molar areas of a left side
of a CTRL rat. b Right side of a CTRL rat having had a molar extraction
showing and increase in vessel density. c Right side of a ZAA rat with a
decreased vascular bed on the right side. White arrows show the alveolar
areas. Green arrows show the vascular pedicle of the nervus alveolaris
inferior. In all images, the scale bar stands for 4 mm
Table 2 qBEI and EDS parameters measured on the alveolar bone of
the left hemimandibles
ZA CTRL p
Capeak (%Ca) 18.57 ± 0.22 18.79 ± 0.34 NS
Camean (%Ca) 18.1 ± 0.19 18.33 ± 0.3 NS
Cawidth (%Ca) 3.3 ± 0.13 3.32 ± 0.17 NS
Ca/P 1.423 ± 0.008 1.420 ± 0.018 NS
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diseases for which zoledronic acid is administered in human
(e.g., osteoporosis, myeloma, bone metastasis) and of other
conditions, cofactors, coexisting systemic diseases, and con-
comitant medications. The aim was to avoid confounding fac-
tors and to demonstrate that BRONJ induction was only due to
BPs. No additional drugs, such as dexamethasone and antibi-
otics, were given to animals. Additional drugs do not seem to
give better results in BRONJ induction [33]. Macroscopic
observations showed a bone exposure in 55% of the ZA treat-
ed animals and none in the control animals in the present
study. Animal models aim at getting a high incidence of
BRONJ: in the literature, varying rates of exposed bone are
found in treated animals (0, 14, 33, 67, and 100%) and none in
controls [33, 42, 45, 47, 50]. A recent review by Mitsimponas
summarizes all animal models of BRONJ that have been de-
veloped [51]. However, bone exposure may be difficult to
evidence because of its limited size and it should not be the
only element to consider in assessing the quality of a BRONJ
model. There was no significant weight difference between
the two groups in the study. Only three comparable models
in the literature report a statistical analysis of weight [41, 44,
52]. Weight is a parameter reflecting the animal welfare. Our
results show that our model with tooth extraction and ZA has
no negative impact on the animal.
In addition to clinical examination, micro-CT is used to
assess the diagnosis of BRONJ in the rat since it provides
3D images and 2D reslicing in different planes. Numerous
images of periosteal apposition and cortical erosion were
found in ZA-treated rats. This has previously been reported
in animal models of BRONJ [42, 53, 54]. Images of bone
sequestration were also found in the present study as in human
BRONJ [53].
Raman microspectroscopy aimed at investigating the pres-
ence of ZA in the bone matrix and to see the influence of this
bisphosphonate on the mineral crystallinity. ZAwas undetect-
able in the impregnated bone of ZA rats because the tissue
concentration are very low [55]. In human bone sequesters
from BRONJ patients, the characteristic bands of ZA could
not be evidenced and an increase in the mineral to organic
ratio was observed [56]. In another study, a decrease of crys-
tallinity, determined with a 632 nm laser, was found in the
newly formed bone in a calvaria defect in ZA-treated rats
[57]. No change in crystallinity was found in the present study
but the wavelength of our laser (785 nm) was different and
another study reporting the Raman spectrum of ZA at 514 nm
also show differences [58]. A SEM study with qBEI analysis
found an increase in the calcium content of the bone matrix in
animals treated during 3 years [59]. In the present study, this
technique failed to identify similar changes, probably due to
the shorter duration of the experiment. In a micro-CT experi-
ment in ZA-treated rats treated up to 6 months, bone mineral
density was found increased at the jaw [60]. Bone quality in rats
treated with alendronate (another amino bisphosphonate) was
found altered with an increased bone mineral density [61].
Analysis of the microvascularization showed that tooth
extraction in CTRL animals increased vascularization in
the mandibular alveolar bone. An increased capillary in-
growth is a normal reaction following tooth extraction
[62]. ZA administration impaired this reactional increased
vascular volume on the right side of ZAA rats. In vitro
antiangiogenic effects of BP have been reported in several
publications [26, 63, 64]. Some animal or human studies
have found that BPs decrease the microvessel density and
circulating endothelial cells and angiogenesis [25, 27–29,
47, 65–67]. This is the first study that analyzed bone mi-
crovascular bed in an animal model of BRONJ by vascular
opacification and micro-CT.
In the present study, an impaired jaw bone vascularization
due to an in vivo antiangiogenic effect of BPs was evidenced.
The hypothesis of an inhibition of angiogenesis due to BPs in
the pathophysiology of BRONJ is thus reinforced. Moreover,
a significant increase of mineralization was found in the alve-
olar bone of ZA rats. This fact is in line with the pathophys-
iological hypothesis of altered bone quality with an increased
stiffness of the bone matrix, due to a uniformity of the miner-
alization degree. The precise role of other pathophysiological
hypotheses is still to be studied: direct toxicity of BPs for
epithelial cells [31], reduced microcirculation of the gingiva,
influence of BPs on immune cells leading to specific infec-
tions (Actynomyces) or osteomyelitis [22, 32]. A recent review
summarizes all the currently advocated hypotheses [24].
In the present study, we aimed at provoking BRONJ in a rat
model with mandibular tooth extraction. Clinical examination
and micro-CT evidenced numerous signs of BRONJ. Our an-
imal model of BRONJ has therefore some limitations.
Mandibular molars extraction is not easy to perform since root
remnants were observed. However, this created mandible
osteonecrosis, a condition that reflects the human disease
which is more frequently observed at the mandible. The
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Fig. 6 3D vascular volume of the alveolar bone (VV/TVALV) for each
group. CRTL rats (empty circles), ZA rats (filled circles). Significant and
nonsignificant differences appear between each group
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clinical and radiographic success rates obtained were lower
than expected but fitted in well with similar studies reported
in the literature.
Conclusion
The animal model described in the present study includes
many elements of micro-CT diagnosis of BRONJ that are
similar to what is found in computed tomography in human
BRONJ [68]. Raman spectroscopy evidenced an increased
mineral to matrix ratio in the alveolar bone after a prolonged
treatment with ZA. SEM-qBEI evidenced no increase in the
calcium content of the bone matrix in treated rats.
Vascularization was increased after tooth extraction in the al-
veolar bone of control animals but was impaired by zoledronic
acid in the same location in treated rats.
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